Organisation paid for research Program year 2021 Source: CMS Open Payments

Kingsley Jeffrey

Neither a doctor nor a teaching hospital

Research payments

$244,729

129 payments

Through program year 2021, Kingsley Jeffrey is reported as receiving $244,729 in research payments, across 129 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$121,719	53
2020	Research	$86,332	70
2019	Research	$36,678	6

Breakdown

Who paid Research payments · program years 2019–2021

AbbVie, Inc. $186,676 120 payments
GlaxoSmithKline, LLC. $36,678 6 payments
Pharmacyclics LLC, An AbbVie Company $21,375 3 payments

Studies the money was for Research payments · program years 2019–2021

Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $37,094 34 payments
A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $36,678 6 payments
M16-100 $35,674 43 payments
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors $21,375 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) $20,850 3 payments
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) $20,675 4 payments
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $17,500 4 payments
M16-049 $14,860 2 payments
M16-142 $12,250 1 payment
M14-702 $11,656 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.